89bio News

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver

GlobeNewswire16:05 ET

89bio Coverage Assumed by B of A Securities at Buy

89bio Coverage Assumed by B of A Securities at Buy

Dow JonesApr 22 06:24 ET

Express News | B of A Securities Assumes 89bio at Buy, Announces Price Target of $30

Moomoo 24/7Apr 22 06:14 ET

Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints

Seeking AlphaApr 19 17:10 ET

89bio Enhances Board With Biopharma Veteran Martin Babler

TipRanksApr 17 16:22 ET

Express News | 89Bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors

Moomoo 24/7Apr 17 16:05 ET

89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors

PDF Version SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovati

89bioApr 17 00:00 ET

89bio Signs Deal for Construction of a Production Facility in China

Seeking AlphaApr 10 17:14 ET

On April 4, 2024, 89Bio Entered Into Collaboration Agreement With BiBo Biopharma Engineering - Filing

BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, if approved. Under the Collaboration Agreement, the Company will pay BiBo

BenzingaApr 10 16:35 ET

Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra

Seeking AlphaApr 9 10:03 ET

89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald

89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald

Dow JonesApr 5 09:33 ET

Express News | Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

Moomoo 24/7Apr 5 09:23 ET

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PDF Version SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and co

89bioApr 5 00:00 ET

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

Yahoo FinanceApr 3 19:01 ET

89bio(ETNB.US) Officer Sells US$575.15K in Common Stock

$89bio(ETNB.US)$ Officer PALEKAR ROHAN sold 52,718 shares of Common Stock on Apr 1, 2024 at an average price of $10.91 for a total value of $575.15K.Source: Announcement What is statement of changes i

moomoo NewsApr 3 16:41 ET

89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing

Rohan Palekar, Director, Chief Executive Officer, on April 01, 2024, sold 52,718 shares in 89bio (ETNB) for $575,153. Following the Form 4 filing with the SEC, Palekar has control over a total of 459,

MT NewswiresApr 3 16:07 ET

Form 144 | 89bio(ETNB.US) Officer Proposes to Sell 574.93K in Common Stocks

SEC FILLINGS DISCLOSED/ Apr 1, $89bio(ETNB.US)$ Officer ROHAN PALEKAR intends to sell 52,718 shares of its common stock on Apr 1, with a total market value of approximately $574.93K. ROHAN PALEKAR h

moomoo NewsApr 1 19:33 ET

Buy Rating Affirmed for 89bio's Pegozafermin: A Promising NASH Treatment With Strong Regulatory Endorsements

TipRanksMar 29 03:09 ET

Express News | HC Wainwright & Co. Maintains Buy on 89bio, Maintains $31 Price Target

Moomoo 24/7Mar 27 13:53 ET

89bio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 170.03% HC Wainwright & Co. $31 → $31 Maintains Buy 03/13/2024 170.03% HC Wainwright & Co. $31

BenzingaMar 27 13:51 ET